{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/vertex-vrtx/",
 "dataUrl": "https://clearank.com/stock/vertex-vrtx/data.json",
 "title": "Vertex Pharma (VRTX) Stock Forecast & Price Target (2026)",
 "description": "Vertex Pharmaceuticals Incorporated (VRTX) stock: Healthcare, Biotechnology. $130.4B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Vertex Pharmaceuticals Incorporated (VRTX)",
 "published": "2026-06-23T09:08:00+00:00",
 "modified": "2026-09-11T02:56:22.421+00:00",
 "generated": "2026-09-11T21:15:10.112Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "VRTX",
  "name": "Vertex Pharmaceuticals Incorporated",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Biotechnology",
  "country": "United States",
  "website": "https://www.vrtx.com"
 },
 "quote": {
  "price": 514.56,
  "previousClose": 521.12,
  "change": -6.56,
  "changePercent": -1.26,
  "open": 519.13,
  "high": 522.59998,
  "low": 514.32001,
  "volume": 815000,
  "averageVolume": 989690,
  "marketCap": 130420853053,
  "fiftyTwoWeekHigh": 560.25,
  "fiftyTwoWeekLow": 374.17001,
  "marketOpen": false,
  "asOf": "2026-09-11T02:56:21.000Z"
 },
 "statistics": {
  "pe": 30.021004,
  "eps": 17.14,
  "dividendYield": 0,
  "beta": 0.32,
  "priceToSales": 10.361386,
  "priceToBook": 6.438358,
  "revenueTtm": 12587200512,
  "grossMargin": 0.8532649449593569,
  "returnOnEquity": 0.23542999
 },
 "technicals": {
  "rsi": 34.86,
  "macd": 7.1,
  "sma50": 510.3,
  "sma200": 467.58,
  "rsiSignal": "Bearish",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 72,
  "consensus": "Buy",
  "fairValue": 577.5,
  "analystTarget": 577.5,
  "analystCount": 30,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-11T02:56:21.000Z",
  "priceAtAnalysis": 514.56,
  "volatility": {
   "daily": 1.98,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 504.27,
  "aggressiveEntry": 514.56,
  "stopLoss": 489.14,
  "stopLossPercent": 3,
  "targets": [
   529.48,
   554.7,
   579.91
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 379.04,
    "base": 576.97,
    "upside90th": 878.26
   },
   {
    "year": 2028,
    "downside10th": 357.12,
    "base": 646.95,
    "upside90th": 1171.99
   },
   {
    "year": 2029,
    "downside10th": 350.38,
    "base": 725.42,
    "upside90th": 1501.89
   },
   {
    "year": 2030,
    "downside10th": 351.05,
    "base": 813.4,
    "upside90th": 1884.73
   },
   {
    "year": 2031,
    "downside10th": 356.46,
    "base": 912.06,
    "upside90th": 2333.68
   },
   {
    "year": 2032,
    "downside10th": 365.41,
    "base": 1022.68,
    "upside90th": 2862.22
   },
   {
    "year": 2033,
    "downside10th": 377.3,
    "base": 1146.72,
    "upside90th": 3485.23
   },
   {
    "year": 2034,
    "downside10th": 391.8,
    "base": 1285.81,
    "upside90th": 4219.71
   },
   {
    "year": 2035,
    "downside10th": 408.77,
    "base": 1441.76,
    "upside90th": 5085.19
   },
   {
    "year": 2036,
    "downside10th": 428.14,
    "base": 1616.63,
    "upside90th": 6104.29
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "VRTX Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$519.13",
    "Day Range": "$514.32 to $522.60",
    "Prev Close": "$521.12",
    "Volume": "815.0K",
    "52-Week Range": "$374.17 to $560.25",
    "Market Cap": "$130.42B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Valuation is broadly in line with sector peers (0.003344% difference), suggesting fair market pricing relative to industry standards."
   ]
  },
  {
   "id": "financials",
   "title": "VRTX Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, VRTX beat estimates 2 times. However, the stock fell 2 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "VRTX Analysis",
   "text": [
    "Vertex Pharmaceuticals Incorporated (VRTX) exhibits bearish momentum as indicated by its RSI of 34.86. The stock is trading below its 20-day exponential moving average of $532.21, suggesting near-term weakness, though it remains above its 50-day and 200-day moving averages ($510.30 and $467.58). Volume has been below average recently, with the latest volume at 815,000 compared to an average of 989,690. Key support levels are found at the 50-day SMA and the 200-day SMA, while resistance may be encountered near the 20-day EMA. The current technical setup suggests a cautious approach, as the bearish RSI and price action below the short-term EMA could precede further downward movement, despite the longer-term upward trend indicated by the SMAs. Investors should watch for a potential bounce from oversold conditions or a break above key resistance levels to confirm a shift in momentum.",
    "Insiders have sold $159.2 million worth of VRTX shares against only $5.8 million in purchases, triggering a 'Heavy Sell Signal' and indicating potential lack of confidence from management.",
    "Vertex Pharmaceuticals missed EPS estimates in its latest reported quarter (August 3, 2026), raising concerns about near-term profitability and execution.",
    "30 Wall Street analysts maintain a 'Buy' rating on VRTX, with a median price target of $577.5, suggesting a 12.2% upside from current levels.",
    "Vertex Pharmaceuticals is expected to achieve 10.00% revenue growth for the current year, reaching an estimated $13.3 billion, indicating strong business expansion.",
    "Vertex Pharmaceuticals Incorporated (VRTX) is expected to see continued growth over the next 6-12 months, supported by a strong 'Buy' consensus from Wall Street and projected revenue increases. The median analyst target price of $577.5 suggests a potential upside of 12.2% from the current price of $514.56, driven by the company's strong pipeline and market position in biotechnology. However, the significant insider selling activity, flagged as a 'Heavy Sell Signal', introduces a notable risk that could impact investor sentiment and potentially pressure the stock price. While the company's longer-term technicals remain supported by its 50-day and 200-day moving averages, the current bearish RSI momentum warrants caution. Investors should monitor upcoming earnings reports and any shifts in insider transaction patterns to gauge the sustainability of the positive outlook."
   ],
   "lists": {
    "ProTips": [
     "Monitor insider transaction patterns closely, as the current 'Heavy Sell Signal' presents a significant risk to VRTX's stock performance.",
     "Given the bearish RSI momentum, consider waiting for a technical confirmation or a pullback to a stronger support level before initiating new positions.",
     "The company's consistent revenue growth and strong analyst backing provide a solid fundamental base, but the significant insider selling warrants a cautious approach to position sizing."
    ]
   },
   "catalysts": [
    {
     "type": "Bearish",
     "title": "Heavy Insider Selling Pressure",
     "text": "Insiders have sold $159.2 million worth of VRTX shares against only $5.8 million in purchases, triggering a 'Heavy Sell Signal' and indicating potential lack of confidence from management.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Recent Earnings Miss",
     "text": "Vertex Pharmaceuticals missed EPS estimates in its latest reported quarter (August 3, 2026), raising concerns about near-term profitability and execution.",
     "source": "Earnings Report"
    },
    {
     "type": "Bullish",
     "title": "Strong Wall Street Buy Consensus",
     "text": "30 Wall Street analysts maintain a 'Buy' rating on VRTX, with a median price target of $577.5, suggesting a 12.2% upside from current levels.",
     "source": "Analyst Ratings"
    },
    {
     "type": "Bullish",
     "title": "Projected Revenue Growth",
     "text": "Vertex Pharmaceuticals is expected to achieve 10.00% revenue growth for the current year, reaching an estimated $13.3 billion, indicating strong business expansion.",
     "source": "Revenue Estimates"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Vertex Pharmaceuticals Incorporated (VRTX) trades at a P/E ratio of 30.02, which is in line with the sector average of 30.02, suggesting a fair valuation relative to its peers. The company is projected to achieve revenue growth of 10.00% for the current year, reaching approximately $13.3 billion, and is expected to grow revenue by another 9.00% next year to $14.5 billion. This consistent revenue expansion is a positive indicator for future profitability and growth. With an EPS of $17.14, VRTX demonstrates solid profitability. The company's balance sheet strength is implied by the absence of reported debt and a sector average debt-to-equity of 0.0, indicating a low-risk financial structure. The current valuation appears justified by its growth prospects and profitability, although the significant insider selling warrants careful consideration.",
    "Vertex Pharmaceuticals Incorporated (VRTX) recently reported mixed earnings results, missing the EPS estimate by 0.42% in its latest quarter (August 3, 2026), with actual EPS at $4.73 versus an estimate of $4.75. This followed a beat in the prior quarter where EPS was $1.17 against an estimate of $1.10, a 6.36% surprise. Prior to that, the company missed expectations by 14.29% in June 2026. Overall, the earnings trend shows inconsistency, with recent performance leaning towards misses, which could be a concern for future performance.",
    "Significant insider selling presents a primary risk for Vertex Pharmaceuticals Incorporated (VRTX), with $159.2 million in sales versus $5.8 million in purchases, indicating a 'Heavy Sell Signal'. The company's recent earnings have also shown inconsistency, with a miss in the latest quarter. Also, the stock's bearish RSI momentum suggests potential for short-term price declines, despite longer-term support from moving averages."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "130.42B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "30.02"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "17.14"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "560.25"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "374.17"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Bearish SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($510.30) above the 200-day SMA ($467.58), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Bearish",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "34.86"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "7.10"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "510.30"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "467.58"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.25",
    "Correlation with Nasdaq 100 (QQQ)": "+0.19",
    "Correlation with Bitcoin (BTC)": "-0.04",
    "Correlation with Gold (XAU)": "+0.12"
   }
  },
  {
   "id": "trade-plans",
   "title": "VRTX Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (34.9) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$529.48",
    "TARGET 2": "$554.70",
    "TARGET 3": "$579.91",
    "STOP LOSS": "$489.14"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+8.88%",
    "Average Feb return": "-2.21%",
    "Average Mar return": "+2.98%",
    "Average Apr return": "+1.72%",
    "Average May return": "+1.22%",
    "Average Jun return": "+4.69%",
    "Average Jul return": "+0.89%",
    "Average Aug return": "+0.58%",
    "Average Sep return": "-2.93%",
    "Average Oct return": "-1.71%",
    "Average Nov return": "+2.81%",
    "Average Dec return": "-0.13%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.98%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in VRTX in September 2016 would be worth about $52,581 today, compared with about $35,030 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in VRTX today could grow to about $31,418 by 2036 in the base case, with a bull case near $118,631 and a bear case around $8,321. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "VRTX Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $813 for VRTX by 2030 in the base case, from $515 today (1.6x over 4 years). The downside path ends near $351. These are outcomes of a Monte Carlo simulation run on VRTX's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using VRTX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "VRTX simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$379",
        "$577",
        "$878"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$357",
        "$647",
        "$1,172"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$350",
        "$725",
        "$1,502"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$351",
        "$813",
        "$1,885"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$356",
        "$912",
        "$2,334"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$365",
        "$1,023",
        "$2,862"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$377",
        "$1,147",
        "$3,485"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$392",
        "$1,286",
        "$4,220"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$409",
        "$1,442",
        "$5,085"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$428",
        "$1,617",
        "$6,104"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "HCA HCA Healthcare, Inc. NYSE $417.37 -1.06%",
     "url": "https://clearank.com/stock/hca-healthcare-hca/"
    },
    {
     "text": "NEOG Neogen Corp. NASDAQ $11.81 +0.3398%",
     "url": "https://clearank.com/stock/neogen-neog/"
    },
    {
     "text": "BSX Boston Scientific Corp. NYSE $43.10 -4.14%",
     "url": "https://clearank.com/stock/boston-scientific-bsx/"
    },
    {
     "text": "RMD ResMed Inc. NYSE $216.92 -1.21%",
     "url": "https://clearank.com/stock/rmd-stock-analysis/"
    },
    {
     "text": "ELV Elevance Health, Inc. NYSE $416.94 +0.0960%",
     "url": "https://clearank.com/stock/elv-stock-analysis/"
    },
    {
     "text": "MCK McKesson Corporation NYSE $880.86 -1.21%",
     "url": "https://clearank.com/stock/mck-stock-analysis/"
    },
    {
     "text": "ABBV AbbVie Inc. NYSE $255.00 +1.63%",
     "url": "https://clearank.com/stock/abbvie-abbv/"
    },
    {
     "text": "MDT Medtronic NYSE $90.78 -0.9223%",
     "url": "https://clearank.com/stock/medtronic-mdt/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Compare VRTX",
   "links": [
    {
     "text": "VRTX vs REGN Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vrtx-vs-regn/"
    },
    {
     "text": "STZ vs TAP Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/stz-vs-tap/"
    },
    {
     "text": "COST vs WMT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/cost-vs-wmt/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "VRTX Insider Trading Analysis",
   "facts": {
    "Bought": "$5.8M",
    "Sold": "$159.2M",
    "Insiders": "23",
    "Avg Transaction": "$2.8M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in VRTX",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Jul 25, 2022",
       "cells": [
        "LEIDEN JEFFREY M Officer and Director",
        "Sell",
        "132.1K",
        "$37.2M"
       ]
      },
      {
       "label": "Nov 14, 2025",
       "cells": [
        "LEIDEN JEFFREY M Officer and Director",
        "Sell",
        "73.3K",
        "$32.3M"
       ]
      },
      {
       "label": "Dec 3, 2025",
       "cells": [
        "LEIDEN JEFFREY M Officer and Director",
        "Sell",
        "63.8K",
        "$28.7M"
       ]
      },
      {
       "label": "Feb 19, 2026",
       "cells": [
        "SACHDEV AMIT Officer",
        "Sell",
        "58.6K",
        "$27.5M"
       ]
      },
      {
       "label": "May 12, 2020",
       "cells": [
        "LEIDEN JEFFREY M Officer and Director",
        "Sell",
        "94.4K",
        "$26.8M"
       ]
      },
      {
       "label": "May 5, 2020",
       "cells": [
        "LEIDEN JEFFREY M Officer and Director",
        "Sell",
        "94.4K",
        "$25.5M"
       ]
      },
      {
       "label": "May 7, 2020",
       "cells": [
        "LEIDEN JEFFREY M Officer and Director",
        "Sell",
        "94.4K",
        "$25.5M"
       ]
      },
      {
       "label": "Feb 27, 2026",
       "cells": [
        "KEWALRAMANI RESHMA Chief Executive Officer",
        "Sell",
        "40.0K",
        "$19.7M"
       ]
      },
      {
       "label": "May 5, 2020",
       "cells": [
        "SACHDEV AMIT Officer",
        "Sell",
        "57.1K",
        "$15.1M"
       ]
      },
      {
       "label": "May 7, 2020",
       "cells": [
        "SACHS BRUCE I Director",
        "Sell",
        "45.0K",
        "$12.1M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Vertex+Pharmaceuticals+Incorporated&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "Is Vertex Pharmaceuticals (VRTX) stock a buy right now?",
   "answer": "Vertex Pharmaceuticals (VRTX) is currently rated a 'Buy' by Wall Street analysts, with a median price target of $577.5, suggesting a 12.2% upside from its current price of $514.56. The company also shows strong revenue growth projections."
  },
  {
   "question": "What is Vertex Pharmaceuticals' (VRTX) fair value?",
   "answer": "The fair value for Vertex Pharmaceuticals (VRTX) is estimated at $577.5, based on the median analyst price target. This represents a potential upside of 12.2% from the current trading price of $514.56."
  },
  {
   "question": "What are the biggest risks for Vertex Pharmaceuticals (VRTX)?",
   "answer": "The primary risks for Vertex Pharmaceuticals (VRTX) include significant insider selling totaling $159.2 million, recent inconsistent earnings performance, and bearish technical momentum indicated by its RSI."
  },
  {
   "question": "What is Vertex Pharmaceuticals' (VRTX) revenue growth outlook?",
   "answer": "Vertex Pharmaceuticals (VRTX) is projected to achieve revenue growth of 10.00% for the current year, with an estimated $13.3 billion in revenue, and is expected to grow revenue by another 9.00% next year to $14.5 billion."
  },
  {
   "question": "How does Vertex Pharmaceuticals (VRTX) compare to its sector averages?",
   "answer": "Vertex Pharmaceuticals (VRTX) trades at a P/E ratio of 30.02, which is in line with the sector average. Its projected revenue growth of 10.00% is also consistent with sector expectations."
  },
  {
   "question": "What is the analyst consensus for Vertex Pharmaceuticals (VRTX)?",
   "answer": "The analyst consensus for Vertex Pharmaceuticals (VRTX) is predominantly 'Buy', with 30 analysts covering the stock. This includes 5 Strong Buys, 19 Buys, 4 Holds, 1 Sell, and 1 Strong Sell, resulting in a Wall Street score of 72 out of 100."
  },
  {
   "question": "What is Vertex Pharmaceuticals' (VRTX) stock forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Vertex Pharmaceuticals' (VRTX) stock forecast for 2030 shows a base case price of $813.4, with a downside projection of $351.05 and an upside projection of $1884.73. These are statistical outcomes, not guaranteed price targets."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "HCA",
    "name": "HCA Healthcare, Inc. NYSE",
    "price": "$417.37",
    "change": "-1.06%",
    "url": "https://clearank.com/stock/hca-healthcare-hca/"
   },
   {
    "ticker": "NEOG",
    "name": "Neogen Corp. NASDAQ",
    "price": "$11.81",
    "change": "+0.3398%",
    "url": "https://clearank.com/stock/neogen-neog/"
   },
   {
    "ticker": "BSX",
    "name": "Boston Scientific Corp. NYSE",
    "price": "$43.10",
    "change": "-4.14%",
    "url": "https://clearank.com/stock/boston-scientific-bsx/"
   },
   {
    "ticker": "RMD",
    "name": "ResMed Inc. NYSE",
    "price": "$216.92",
    "change": "-1.21%",
    "url": "https://clearank.com/stock/rmd-stock-analysis/"
   },
   {
    "ticker": "ELV",
    "name": "Elevance Health, Inc. NYSE",
    "price": "$416.94",
    "change": "+0.0960%",
    "url": "https://clearank.com/stock/elv-stock-analysis/"
   },
   {
    "ticker": "MCK",
    "name": "McKesson Corporation NYSE",
    "price": "$880.86",
    "change": "-1.21%",
    "url": "https://clearank.com/stock/mck-stock-analysis/"
   },
   {
    "ticker": "ABBV",
    "name": "AbbVie Inc. NYSE",
    "price": "$255.00",
    "change": "+1.63%",
    "url": "https://clearank.com/stock/abbvie-abbv/"
   },
   {
    "ticker": "MDT",
    "name": "Medtronic NYSE",
    "price": "$90.78",
    "change": "-0.9223%",
    "url": "https://clearank.com/stock/medtronic-mdt/"
   }
  ],
  "comparisons": [
   {
    "ticker": "VRTX vs REGN Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vrtx-vs-regn/"
   },
   {
    "ticker": "STZ vs TAP Comparison",
    "name": "",
    "url": "https://clearank.com/compare/stz-vs-tap/"
   },
   {
    "ticker": "COST vs WMT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/cost-vs-wmt/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "BRO",
    "text": "Brown & Brown Inc.",
    "url": "https://clearank.com/stock/bro-stock-analysis/"
   },
   {
    "ticker": "SYY",
    "text": "Sysco Corp.",
    "url": "https://clearank.com/stock/syy-stock-analysis/"
   },
   {
    "ticker": "FIS",
    "text": "Fidelity National Information Services, Inc.",
    "url": "https://clearank.com/stock/fis-stock-analysis/"
   },
   {
    "ticker": "EXC",
    "text": "Exelon Corp.",
    "url": "https://clearank.com/stock/exc-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "REPL",
    "text": "↓ 8.37%",
    "url": "https://clearank.com/stock/repl-stock-analysis/"
   },
   {
    "ticker": "ALGO/USD",
    "text": "↓ 8.21%",
    "url": "https://clearank.com/crypto/algorand-algo-usd/"
   },
   {
    "ticker": "SOXL",
    "text": "↓ 8.03%",
    "url": "https://clearank.com/etf/direxion-semiconductor-bull-soxl/"
   },
   {
    "ticker": "NEAR/USD",
    "text": "↑ 18.46%",
    "url": "https://clearank.com/crypto/near-protocol-near-usd/"
   },
   {
    "ticker": "THETA/USD",
    "text": "↑ 15.25%",
    "url": "https://clearank.com/crypto/theta-network-theta-usd/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "REGN",
    "text": "Regeneron Pharmaceuticals",
    "url": "https://clearank.com/stock/regeneron-regn/"
   },
   {
    "ticker": "REPL",
    "text": "Replimune",
    "url": "https://clearank.com/stock/repl-stock-analysis/"
   },
   {
    "ticker": "RGNX",
    "text": "REGENXBIO",
    "url": "https://clearank.com/stock/rgnx-stock-analysis/"
   },
   {
    "ticker": "RXRX",
    "text": "Recursion",
    "url": "https://clearank.com/stock/rxrx-stock-analysis/"
   },
   {
    "ticker": "VKTX",
    "text": "Viking Therapeutics Inc",
    "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "url": "https://clearank.com",
     "sameAs": [
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "email": "info@clearank.com",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise",
     "numberOfEmployees": {
      "@type": "QuantitativeValue",
      "value": "40"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/06/vrtx-analysis-2026-06.png",
     "url": "https://clearank.com/wp-content/uploads/2026/06/vrtx-analysis-2026-06.png",
     "width": "1280",
     "height": "720",
     "caption": "Vertex Pharmaceuticals (VRTX) stock price analysis chart for June 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/vertex-vrtx/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/vertex-vrtx/",
        "name": "Vertex Pharmaceuticals (VRTX) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/vertex-vrtx/#webpage",
     "url": "https://clearank.com/stock/vertex-vrtx/",
     "name": "Vertex Pharma (VRTX) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-06-23T09:08:00+00:00",
     "dateModified": "2026-09-11T02:56:22+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/vrtx-analysis-2026-06.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/vertex-vrtx/#breadcrumb"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/writer/clearank/",
     "name": "CleaRank",
     "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.",
     "url": "https://clearank.com/writer/clearank/",
     "image": {
      "@type": "ImageObject",
      "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "caption": "CleaRank",
      "inLanguage": "en-US"
     },
     "sameAs": [
      "https://clearank.com/",
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     },
     "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg"
    },
    {
     "@type": "Article",
     "headline": "Vertex Pharma (VRTX) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-06-23T09:08:00+00:00",
     "dateModified": "2026-09-11T02:56:22+00:00",
     "author": {
      "@id": "https://clearank.com/writer/clearank/",
      "name": "CleaRank"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "description": "Vertex Pharmaceuticals Incorporated (VRTX) stock: Healthcare, Biotechnology. $130.4B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "name": "Vertex Pharma (VRTX) Stock Forecast & Price Target (2026)",
     "@id": "https://clearank.com/stock/vertex-vrtx/#richSnippet",
     "isPartOf": {
      "@id": "https://clearank.com/stock/vertex-vrtx/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/vrtx-analysis-2026-06.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/vertex-vrtx/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FinancialProduct",
   "name": "Vertex Pharmaceuticals Incorporated (VRTX)",
   "tickerSymbol": "VRTX",
   "url": "https://clearank.com/stock/vertex-vrtx/",
   "description": "AI-powered financial analysis for Vertex Pharmaceuticals Incorporated (VRTX) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.",
   "exchange": "NASDAQ",
   "offers": {
    "@type": "Offer",
    "price": 514.56,
    "priceCurrency": "USD",
    "availability": "https://schema.org/InStock",
    "url": "https://clearank.com/stock/vertex-vrtx/",
    "priceValidUntil": "2026-09-12"
   }
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Is Vertex Pharmaceuticals (VRTX) stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Vertex Pharmaceuticals (VRTX) is currently rated a 'Buy' by Wall Street analysts, with a median price target of $577.5, suggesting a 12.2% upside from its current price of $514.56. The company also shows strong revenue growth projections."
     }
    },
    {
     "@type": "Question",
     "name": "What is Vertex Pharmaceuticals' (VRTX) fair value?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The fair value for Vertex Pharmaceuticals (VRTX) is estimated at $577.5, based on the median analyst price target. This represents a potential upside of 12.2% from the current trading price of $514.56."
     }
    },
    {
     "@type": "Question",
     "name": "What are the biggest risks for Vertex Pharmaceuticals (VRTX)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The primary risks for Vertex Pharmaceuticals (VRTX) include significant insider selling totaling $159.2 million, recent inconsistent earnings performance, and bearish technical momentum indicated by its RSI."
     }
    },
    {
     "@type": "Question",
     "name": "What is Vertex Pharmaceuticals' (VRTX) revenue growth outlook?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Vertex Pharmaceuticals (VRTX) is projected to achieve revenue growth of 10.00% for the current year, with an estimated $13.3 billion in revenue, and is expected to grow revenue by another 9.00% next year to $14.5 billion."
     }
    },
    {
     "@type": "Question",
     "name": "How does Vertex Pharmaceuticals (VRTX) compare to its sector averages?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Vertex Pharmaceuticals (VRTX) trades at a P/E ratio of 30.02, which is in line with the sector average. Its projected revenue growth of 10.00% is also consistent with sector expectations."
     }
    },
    {
     "@type": "Question",
     "name": "What is the analyst consensus for Vertex Pharmaceuticals (VRTX)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The analyst consensus for Vertex Pharmaceuticals (VRTX) is predominantly 'Buy', with 30 analysts covering the stock. This includes 5 Strong Buys, 19 Buys, 4 Holds, 1 Sell, and 1 Strong Sell, resulting in a Wall Street score of 72 out of 100."
     }
    },
    {
     "@type": "Question",
     "name": "What is Vertex Pharmaceuticals' (VRTX) stock forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Vertex Pharmaceuticals' (VRTX) stock forecast for 2030 shows a base case price of $813.4, with a downside projection of $351.05 and an upside projection of $1884.73. These are statistical outcomes, not guaranteed price targets."
     }
    }
   ]
  }
 ]
}